行情

IMMP

IMMP

Immutep
NASDAQ

实时行情|Nasdaq Last Sale

4.690
+0.090
+1.96%
停牌 17:50 06/16 EDT
开盘
4.550
昨收
4.690
最高
4.770
最低
4.550
成交量
16.60万
成交额
--
52周最高
7.95
52周最低
1.030
市值
3.04亿
市盈率(TTM)
-1.0829
分时
5日
1月
3月
1年
5年
Immutep TACTI-002 和 INSIGHT 临床结果和更新全球网络广播幻灯片(链接)
https://www.immutep.com/files/content/investor/presentation/2021/ASCO%202021/2021-06-09_ASCO2021_Global%20Webcast%20Slides.pdf
Benzinga · 06/09 10:45
Brief-Immutep 揭示了一个新的 Anti-Lag-3 研究计划
reuters.com · 06/08 12:27
Immutep 在 ASCO 2021 上强调了来自首席肿瘤学候选人的令人鼓舞的数据
Benzinga · 06/04 14:31
Brief-Immutep 获得 Eftilagimod Alpha 的第二项欧洲专利,这是一种可溶性 Lag-3 蛋白,与 Pd-1 通路抑制剂联合使用
reuters.com · 06/02 12:30
Immutep 获得 Eftilagimod Alpha 的第二项欧洲专利,这是一种可溶性 LAG-3 蛋白,与 PD-1 通路抑制剂联合使用
Immutep Limited (NASDAQ: IMMP) is pleased to announce the grant of patent numberEP3473263 entitled "Combined Preparations for the Treatment of Cancer" by the European Patent Office.
Benzinga · 06/02 09:22
Immutep 获得欧洲癌症联合疗法专利
MT Newswires · 06/02 08:43
36 只股票在周二的中盘交易
Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares jumped 67.3% to $5.94 after the company announced its subsidiary, Gibson Technical Services, reached an agreement with TEC on a 700-mile engineering and construction project across central Mississippi...
Benzinga · 06/01 16:00
Immutep 与默克德国合作进行 Eftilagimod/Bintrafusp 联合试验实体瘤
Benzinga · 06/01 13:05
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解IMMP最新的财务预测,通过IMMP每股收益,每股净资产,每股现金流等数据分析Immutep近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测IMMP价格均价为8.22,最高价位8.71,最低价为7.74。
EPS
机构持股
总机构数: 21
机构持股: 502.22万
持股比例: 7.74%
总股本: 6,487.25万
类型机构数股数
增持
4
168.53万
建仓
5
269.13万
减持
1
9,969
平仓
1
2.45万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.57%
制药与医学研究
-0.98%
高管信息
Non-Executive Chairman
Russell Howard
Chief Executive Officer/Executive Director
Marc Voigt
Non-Executive Vice Chairman
Pete Meyers
Chief Operating Officer/General Counsel/Secretary
Deanne Miller
Chief Scientific Officer
Frederic Triebel
Non-Executive Director
Grant Chamberlain
暂无数据
IMMP 简况
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

微牛提供Immutep Ltd(NASDAQ-IMMP)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IMMP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IMMP股票基本功能。